Actually, looks like our new SAB member will be presenting our results, Dr. Mazen Noureddin
Presentation Listing for Dr. Mazen Noureddin
He sounds like he will represent us very well!
Presentation Listing for Dr. Mazen Noureddin
Quote:Mazen Noureddin, MD, MHSc, is the founding director of the Fatty Liver Program at Cedars-Sinai Medical Center (currently ranked #2 in GI and GI surgery per US News). Dr. Noureddin did his internal medicine residency at the University of Southern California (USC) and then moved to the National Institutes of Health (NIH), where he enrolled in a three-year hepatology fellowship at the Liver Diseases Branch of the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). There, he finished the NIH/Duke University Master of Health Sciences in Clinical Research program. After completing his NIH fellowship, he completed a gastroenterology fellowship at the University of California, San Diego (UCSD), where he was a T32 NIH fellow. He then joined the University of Southern California (USC) as an Assistant Professor of Clinical Medicine in 2013. He was then recruited to Cedars-Sinai Medical Center in 2015 to establish its new fatty liver program. Dr. Noureddin is internationally known for his research in the area of NAFLD/NASH and NASH related cirrhosis. He conducted more than 40 investigational clinical studies of novel treatments for NASH. In addition, he is an expert in non-invasive testing and biomarkers of the field, especially serum biomarkers, trainset elastography, and magnetic resonance imaging techniques. He has published in all these areas and has been invited to consensus panels on this topic by multiple societies including the American Association for the Study of Liver Diseases (AASLD) and European Association for the Study of Liver Diseases (EASL). He has given invited lectures on NAFLD/NASH at national and international society meetings and serves on several steering committees/advisory boards for industry. He is the vice chair of the AASLD NASH special interest group (will be chairing the group in 2023) and serves on the editorial board for major GI journals including “Gastroenterology”, “Hepatology” and “Clinical Gastroenterology and Hepatology (CGH)”. He is one of the new Associate Editors of “Clinical Gastroenterology and Hepatology (CGH)” starting 2022. He is funded by the National Cancer Institute and has served as a reviewer on NIH study section. He has published in many journals including: The Lancet, Science Trinational Medicine, Journal of Hepatology, Journal of Clinical Investigation, Gastroenterology, Hepatology, Clinical Gastroenterology and Hepatology and others
Quote:Use of second-harmonic generation microscopy for automated detection of septa and nodules in needle liver biopsies of NASH cirrhosis 24 June 2022 09:00 - 09:00
Derivation of machine learning histologic scores correlating with portal pressures and the development of varices in NASH patients with cirrhosis 24 June 2022 09:00 - 09:00
The MRI and AST (MAST) score is correlated with noninvasive and histologic markers of fibrosis in patients with advanced fibrosis due to NASH 24 June 2022 09:00 - 09:00
Cost utility analysis for screening for fibrotic NASH in the type 2 population from European countries 24 June 2022 09:00 - 09:00
Favorable safety profile of TERN-201, a highly selective inhibitor of vascular adhesion protein-1, in the nonalcoholic steatohepatitis phase 1b AVIATION study 25 June 2022 09:00 - 09:00
Efficacy and safety of leronlimab in patients with nonalcoholic steatohepatitis: topline results of NASH01 clinical trial 25 June 2022 09:00 - 09:00
He sounds like he will represent us very well!
20
